Welcome to LookChem.com Sign In|Join Free

CAS

  • or

107097-80-3

Post Buying Request

107097-80-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

107097-80-3 Usage

Description

Loxiglumide is a cholecystokinin type 1 (CCK1) receptor antagonist, which is a chemical compound that specifically targets and blocks the CCK1 receptor. It is known for its ability to suppress cholecystokinin-induced proliferation of acinar cells and inhibit pancreatic secretion of digestive enzymes. Loxiglumide has demonstrated activity in vivo, making it a potential candidate for various therapeutic applications.

Uses

Used in Pharmaceutical Industry:
Loxiglumide is used as a therapeutic agent for the treatment of pancreatic diseases, particularly those involving the overproduction of digestive enzymes and the proliferation of acinar cells. Its ability to inhibit pancreatic secretion and suppress acinar cell proliferation makes it a promising option for managing conditions such as chronic pancreatitis.
Used in Research Applications:
Loxiglumide is also used as a research tool in the study of cholecystokinin and its role in various physiological processes. As a CCK1 receptor antagonist, it can help researchers understand the specific functions of the CCK1 receptor and its involvement in pancreatic enzyme secretion, cell proliferation, and other related pathways.
Used in Drug Development:
In the field of drug development, Loxiglumide serves as a lead compound for the development of new medications targeting the CCK1 receptor. Its antagonistic properties can be leveraged to create more potent and selective drugs for the treatment of pancreatic disorders and potentially other conditions related to cholecystokinin signaling.

Biochem/physiol Actions

Loxiglumide is a small-molecule antagonist of the cholecystokinin receptor CCKA. Loxiglumide inhibits pancreatic secretion of digestive enzymes, and also blocks CCK-induced gastric secretions and emptying.

Safety Profile

A poison by intravenous. Moderately toxic by ingestion, intraperitoneal, and subcutaneous routes. When heated to decomposition it emits toxic vapors of NOx and Cl-.

Check Digit Verification of cas no

The CAS Registry Mumber 107097-80-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,7,0,9 and 7 respectively; the second part has 2 digits, 8 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 107097-80:
(8*1)+(7*0)+(6*7)+(5*0)+(4*9)+(3*7)+(2*8)+(1*0)=123
123 % 10 = 3
So 107097-80-3 is a valid CAS Registry Number.
InChI:InChI=1/C21H30Cl2N2O5/c1-3-4-5-11-25(12-6-13-30-2)21(29)18(9-10-19(26)27)24-20(28)15-7-8-16(22)17(23)14-15/h7-8,14,18H,3-6,9-13H2,1-2H3,(H,24,28)(H,26,27)

107097-80-3 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Sigma

  • (SML0130)  Loxiglumide  ≥97% (HPLC)

  • 107097-80-3

  • SML0130-10MG

  • 856.44CNY

  • Detail
  • Sigma

  • (SML0130)  Loxiglumide  ≥97% (HPLC)

  • 107097-80-3

  • SML0130-50MG

  • 3,474.90CNY

  • Detail

107097-80-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-[(3,4-dichlorobenzoyl)amino]-5-[3-methoxypropyl(pentyl)amino]-5-oxopentanoic acid

1.2 Other means of identification

Product number -
Other names Loxiglumide

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:107097-80-3 SDS

107097-80-3Upstream product

107097-80-3Downstream Products

107097-80-3Related news

LOXIGLUMIDE (cas 107097-80-3) inhibits cholecystokinin stimulated somatostatin secretion and simultaneously enhances gastric acid secretion in humans08/16/2019

In vitro studies have demonstrated that cholecystokinin releases somatostatin from the gastric mucosa. To date, there is no information about the in vivo significance of this finding in man. Therefore, we have studied the effect of infusion of cholecystokinin resulting in plasma concentrations w...detailed

Satiety effects of the type A CCK receptor antagonist LOXIGLUMIDE (cas 107097-80-3) in lean and obese women08/15/2019

Several studies have demonstrated that administration of cholecystokinin (CCK) reduces food intake in several species, including humans. In animal studies CCK-receptor antagonists have been reported to increase food intake, suggesting a physiological satiety effect of CCK in these animals. In a ...detailed

Treatment with cholecystokinin receptor antagonist LOXIGLUMIDE (cas 107097-80-3) enhances insulin response to intravenous glucose stimulation in postpancreatitic rats08/14/2019

Pancreatic exocrine and endocrine function in postpancreatitic rats treated with cholecystokinin (CCK) receptor antagonist loxiglumide was compared with that treated with saline and CCK octapeptide (CCK-8) or with that in normal control rats. Treatment with loxiglumide (50 mg/kg body weight), CC...detailed

Effect of the specific cholecystokinin-receptor antagonist LOXIGLUMIDE (cas 107097-80-3) on bombesin stimulated pancreatic enzyme secretion in man08/13/2019

We have investigated the effects of the specific cholecystokinin (CCK) receptor antagonist loxiglumide on basal and bombesin stimulated pancreatic enzyme secretion, bilirubin output and plasma CCK release in six healthy subjects. The data were compared with those obtained in control experiments ...detailed

The effects on diet, anastomotic type, and LOXIGLUMIDE (cas 107097-80-3) on gastric emptying following gastrojejunostomy08/10/2019

PurposeThe effects on gastric emptying of feeding with a normal diet (ND), an early high-calorie and hyperosmolar diet (HCHOD) or normal diet plus intraperitoneal loxiglumide (LOX) were investigated in rats with antecolic (ACGJ) or retrocolic (RCGJ) gastrojejunostomy.detailed

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 107097-80-3